Showing results (11-20 of 43) with videos related to
Sort By:
Pageof 5
Current Medical Research and Opinion|June 29, 2007
Systematic review and meta-analysis of budesonide/formoterol in a single inhalerSteven J Edwards, Kevin Gruffydd-Jones, Dermot P RyanCurrent Medical Research and Opinion|June 23, 2005
Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infectionsSteven J Edwards, Cathy E Emmas, Helen E CampbellHealth Technology Assessment (Winchester, England)|April 2, 2016
Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluationElizabeth Thurgar, Samantha Barton, Charlotta Karner, et al.Health Technology Assessment (Winchester, England)|January 29, 2015
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluationSteven J Edwards, Samantha Barton, Elizabeth Thurgar, et al.Health Technology Assessment (Winchester, England)|July 1, 2026
Ethical implications of the use of AI-based technologies for medical image classification systems in screening: a qualitative systematic reviewMelina Vasileiou, Victoria Wakefield, Clare Dadswell, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 21, 2024
Challenges of Incorporating Life Cycle Drug Pricing in Cost-Effectiveness Models: A Review of Methods and Modeling SuggestionsMathilde Puls, James Horscroft, Benjamin Kearns, et al.Clinical Therapeutics|August 30, 2003
A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitisAnan S Raghunath, Jonathan R B Green, Steven J EdwardsPharmacoeconomics|January 11, 2021
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell CarcinomaSven L Klijn, Elisabeth Fenwick, Sonja Kroep, et al.Pharmacoeconomics - Open|July 3, 2021
Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision MakingJason Gordon, Angela Stainthorpe, Beverley Jones, et al.Pharmacoeconomics|November 23, 2018
Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology AppraisalBecky Pennington, Shije Ren, Samantha Barton, et al.Pageof 5